Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Jamie Aye
Assistant Professor
Close
E-mail
jamieaye@uab.edu
Visualizations
Co-author Network
Map of Science
Co-investigator Network
Jamie Aye
Assistant Professor
Positions
Assistant Professor (P)
,
Pediatric - Hematology-Oncology
,
Pediatrics
Publications
Research
Background
Contact
Publications
Selected Publications
Academic Article
Filter
Year
Title
Altmetric
2022
Comment on: Patients with nonmetastatic embryonal rhabdomyosarcoma arising in the biliary tract should be treated on low-risk clinical trials
.
Pediatric Blood and Cancer
. 69.
2022
2022
Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy
.
Cancers
. 14.
2022
2021
PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma
.
Scientific Reports
. 11.
2021
2021
Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor
.
Translational Oncology
. 14.
2021
2021
Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts
.
Journal of Pediatric Surgery
. 56:1165-1173.
2021
2021
PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma
.
Journal of Pediatric Surgery
. 56:1157-1164.
2021
2021
Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group
.
Pediatric Blood and Cancer
. 68.
2021
2021
EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth
.
PLoS One
. 16.
2021
2021
9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts
.
Translational Oncology
. 14.
2021
2021
To Disclose or Not to Disclose: A Case Highlighting the Challenge of Conflicts in Pediatric Disclosure
.
Journal of Pain and Symptom Management
. 61:211-215.
2021
2020
Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group
.
Pediatric Blood and Cancer
. 67.
2020
2020
Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high-grade metastatic tumor with rhabdoid and focal neuroendocrine features
.
Pediatric Blood and Cancer
. 67.
2020
2019
Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts
.
Scientific Reports
. 9.
2019
2019
Corruption of neuroblastoma patient derived xenografts with human T cell lymphoma
.
Journal of Pediatric Surgery
. 54:2117-2119.
2019
2019
UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts
.
Translational Oncology
. 12:1364-1374.
2019
2019
The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival
.
Journal of Pediatric Surgery
. 54:1206-1213.
2019
2019
PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells
.
PLoS One
. 14.
2019
2019
Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma
.
Translational Oncology
. 12:200-208.
2019
2019
Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth
.
Translational Oncology
. 12:84-95.
2019
2019
The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor
.
Oncotarget
. 10:5534-5548.
2019
2018
FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
.
Scientific Reports
. 8.
2018
2018
UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts
.
Journal of Neuro-Oncology
. 140:209-224.
2018
2018
Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma
.
Oncotarget
. 9:22665-22679.
2018
2008
Effects of disrupting calcium homeostasis on neuronal maturation: early inhibition and later recovery.
.
Cellular and Molecular Neurobiology
. 28:389-409.
2008
Chapter
Filter
Year
Title
Altmetric
2019
Role of stemness factors in neuroblastoma
. 187-202.
2019
Research
Principal Investigator On
An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Investigator On
A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ANBL1531-JDI- A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL),”
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
APEC1621I -NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
APEC1621SC - PEDIATRIC MATCH PCR - COG FOUNDATION
awarded by
CHILDREN'S ONCOLOGY GROUP
ARST1921, A Safety, Pharmacokinetic and Efficacy Study of a ?-Secretase Inhibitor, Nirogacestat(PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors -AR10441
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
ARST1921, A Safety, Pharmacokinetic and Efficacy Study of y-Secretase Inhibitor, Nirogacestat (PF03084014:IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
CTSU: Phase II Supplemental Payments (N02-CM-62212)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
CTSU: Phase ll Supplemental Payments (N02-CM-62212)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Development, Maintenance and Utilization of a Pediatric Solid Tumor Xenograft Bank
awarded by
THE CHILDREN'S HOSPITAL OF ALABAMA
Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
MCC 18613 Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 18613, Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 19487 A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with 5-Azacytidine in Patients with Recurrent, Resectable Osteosarcoma
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 20339 Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
NIH COG Phase I Grant
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Per Case Reimbursement COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Phase 1-11 Study of MEK 162 for Children with Progressive or Recurrent Cancer and A Phase 11 Study of Children with Low- Grade Gliomas and Other Ras/ RAF/MAP Pathway Activated Tumors
awarded by
CHILDREN'S HOSPITAL LA
Preclinical Evaluation of M002, a Novel Oncolytic Herpes Simplex Virus, in Fusion-Positive Rhabdomyosarcoma
awarded by
NATIONAL PEDIATRIC CANCER FOUNDATION
Private Grant
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Private Grant
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
EISAI, INC.
Private Grant
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Private Grant
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Project EveryChild APEC14B1
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
St. Baldricks Fdn Supplemental Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Transforming Pediatric Oncology Healthcare Through Family Navigation
awarded by
UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
Workload Intensity NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) -PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Background
Education And Training
Doctor of Medicine,
Mercer University
2012
Contact
Full Name
Jamie
Aye